CytomX Therapeutics, Inc. (CTMX) Stock Forecast
CTMX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.62 / 5 from 8 analysts
- Price target
- $12.25 average of analyst targets
- Upside to target
- +437.3% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.09
- 52-week range
- $2.23 – $6.75
CTMX analyst ratings
8 analystsNumber of analysts at each rating.
CTMX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CTMX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.07 | −$0.11 | $0.03 | −$0.09 | +21.4% | 7 |
| Current fiscal year (2026) | −$0.39 | −$0.52 | −$0.28 | −$0.15 | −159.2% | 7 |
| Next fiscal year (2027) | −$0.47 | −$0.67 | −$0.16 | −$0.39 | −21.0% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CTMX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $10.4M | $2.0M | $37.0M | +75.2% | 6 |
| Current fiscal year (2026) | $25.0M | $10.3M | $53.7M | −67.2% | 6 |
| Next fiscal year (2027) | $25.3M | $0 | $84.7M | +1.2% | 6 |
CTMX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CTMX revenue: reported and forecast
CTMX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.11 | −$0.07 | −$0.07 | −$0.07 | −$0.07 | −32.7% | 4 up · 1 down |
| Current fiscal year (2026) | −$0.42 | −$0.39 | −$0.39 | −$0.39 | −$0.39 | −7.6% | 4 up · 1 down |
| Next fiscal year (2027) | −$0.49 | −$0.47 | −$0.47 | −$0.47 | −$0.47 | −3.2% | 4 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CTMX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CTMX beat in 9 of 12.
What analysts expect from CTMX
8 analysts cover CytomX Therapeutics; their consensus rating is strong buy (4.62 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.25, 437.3% above the latest close of $2.28. Analysts expect earnings of −$0.39 per share for 2026, −159.2% from a year earlier. For 2027 the average estimate is −$0.47 per share on revenue of $25.3 million. CytomX Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: CTMX income statement, CTMX key metrics, CTMX chart. See the CTMX stock overview for the latest quote and news.
CTMX forecast FAQ
What is CytomX Therapeutics's price target?
The average analyst price target for CytomX Therapeutics is $12.25, 437.3% above the latest close of $2.28.
Is CytomX Therapeutics a buy, hold or sell?
Of 8 analysts covering CytomX Therapeutics, 5 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is CytomX Therapeutics's EPS forecast?
Analysts forecast −$0.39 per share for 2026 (range −$0.52 to −$0.28); for 2027 the estimate is −$0.47.
What is CytomX Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $25.0 million, growth of −67.2%; for 2027 it is $25.3 million.
When does CytomX Therapeutics report earnings?
CytomX Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.09.
Does CytomX Therapeutics usually beat earnings estimates?
CytomX Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.